Bio-Thera Solutions, Ltd. (SHA:688177)

Market Cap	8.87B
Revenue (ttm)	743.17M
Net Income (ttm)	-510.30M
Shares Out	414.08M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	76.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,361,961
Average Volume	3,996,032
Open	21.50
Previous Close	21.72
Day's Range	20.90 - 21.88
52-Week Range	17.70 - 35.78
Beta	0.43
RSI	50.40
Earnings Date	Apr 9, 2025

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. The company offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 1,167
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688177

Financial Performance

In 2024, Bio-Thera Solutions's revenue was 743.17 million, an increase of 5.44% compared to the previous year's 704.79 million. Losses were -510.30 million, 29.3% more than in 2023.